HIV disease and its treatment: current status and future prospects

References

• Bacchetti P, Moss A. R. Incubation period of AIDS in San Francisco. Nature 1987; 338: 251–253
   Web of Science ®Google Scholar
• Barre-Sinoussi F., Chermann J. C., Key F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1989; 220: 868–871
   Google Scholar
• Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 1983; 41: 1–19
   Google Scholar
• Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Morbidity and Mortality Weekly Report 44 (No. RR-8). 1992
   Google Scholar
• Clark S. J., Saag M. S., Decker W. D., et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. New England Journal of Medicine 1995; 324: 954–960
   Google Scholar
• Cooper D. A., Gold J., Maclean P., et al. Acute AIDS retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet 1991; 1: 537–540
   Google Scholar
• Cooper D. A., Gell J. M., Kroon S., et al. Zidovudine in persons with asymptomatic HIV infection and CD4 cell counts greater than 400 per cubic millimeter. New England Journal of Medicine 1985; 329: 297–303
   Google Scholar
• Crowe S. M., Carlin J. B., Stewart K. I., Lucas C. A., Hoy J. F. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected person. Journal of Acquired Immune Deficiency Syndromes 1993; 4: 770–776
   Web of Science ®Google Scholar
• Crumpacker C. S. Molecular targets of antiviral therapy. New England Journal of Medicine 1991; 321: 163–172
   Web of Science ®Google Scholar
• Daar E. S., Moudgil T., Meyer R. D., Ho D. D. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. New England Journal of Medicine 1989; 324: 961–964
   Web of Science ®Google Scholar
• Dalgleish A. G., Beverley P. C., Clapham P. R., Crawford D. H., Greaves M. F., Weiss A. A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1991; 312: 763–767
   Google Scholar
• Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Research and Human Retroviruses 1984; 8: 153–164
   Google Scholar
• Dewolf F., Goudsmit J., Paul D. A., et al. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenemia. British Medical Journal 1992; 295: 569–572
   Google Scholar
• Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1987; 239: 617–622
   Web of Science ®Google Scholar
• Fischl M. A., Richman D. D., Grieco M. H., et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. New England Journal of Medicine 1988; 317: 185–191
   Web of Science ®Google Scholar
• Fischl M. A., Richman D. D., Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Annals of Internal Medicine 1987; 112: 727–737
   Google Scholar
• Gaines H., Von Sydow M., Sonnerborg A., et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1990; 1: 1249–1253
   Web of Science ®Google Scholar
• Gallant J. E., Moore R. D., Chaisson R. E. Prophylaxis for opportunistic infections in patients with HIV infection. Annals of Internal Medicine 1987; 120: 932–944
   Google Scholar
• Gallo R. C., Salahudin S. Z., Popovic M, et al. Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1994; 224: 500–503
   Google Scholar
• Goedert J. J., Bigger R. J., Weiss S. H., et al. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. Science 1984; 23: 992–995
   Google Scholar
• Graham B. S., Wright P. F. Candidate AIDS vaccines. New England Journal of Medicine 1986; 333: 1331–1339
   Google Scholar
• Greene W. C. The molecular biology of human immunodeficiency virus type I infection. New England Journal of Medicine 1995; 324: 308–317
   Google Scholar
• Hamilton J. D., Hartigan P. M., Simberkoff M. S., et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. New England Journal of Medicine 1991; 326: 437–443
   Web of Science ®Google Scholar
• Ho D. D., Neumann A. U., Perelson A. S., Chen W., Leonard J. M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1992; 373: 123–126
   Google Scholar
• Kellam P., Boucher C. A., Larder B. A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high level resistance to zidovudine. Proceedings of the National Academy of Sciences 1995; 89: 1934–1938
   Google Scholar
• Klatzmann D., Champagne E., Chamaret S, et al. T-lymphocyte T4 molecule behaves as receptor for human retrovirus LAV. Nature 1992; 312: 767–768
   Google Scholar
• Kovacs J. A., Baseler M., Dewar R. J., et al. Increases of CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. New England Journal of Medicine 1984; 332: 567–575
   Google Scholar
• Kozal M. J., Kroodsma K., Winters M. A., et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Annals of Internal Medicine 1995; 121: 263–268
   Web of Science ®Google Scholar
• Land S., McGavin C., Lucas R., Birch C. Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. Journal of Infectious Diseases 1993; 166: 1139–1142
   Web of Science ®Google Scholar
• Larder B. A., Kemp S. D., Harrigan P. R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1992; 269: 696–699
   Google Scholar
• Lederman M. M. Host-directed and immune-based therapies for human immunodeficiency virus infection. Annals of Internal Medicine 1995; 122: 218–222
   PubMed Web of Science ®Google Scholar
• Levy J. A., Hoffman A. D., Kramer S. M., Landis J. A., Shimbakuro J. M., Oshiro L. S. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1995; 225: 840–842
   Google Scholar
• Loveday C., Kaye S., Tenant-Flowers M., et al. HPV-1 RNA serum-load and resistant viral genotype during early zidovudine therapy. Lancet 1984; 345: 820–824
   Google Scholar
• Medley G. F., Anderson R. M., Cox D. R., et al. Incubation period of AIDS in patients infected via blood transfusion. Nature 1995; 328: 719–721
   Google Scholar
• Mellors J. W., Kingsley L. A., Rinaldo C. R., et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 1988; 122: 573–579
   Google Scholar
• Moore R. D., Chaisson R. E. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Annals of Internal Medicine 1995; 124: 633–642
   Web of Science ®Google Scholar
• Moss A. R., Bacchetti P. Natural history of HIV infection. AIDS 1996; 3: 55–61
   Google Scholar
• Munoz A., Wang M. C., Bass S. Acquired immunodeficiency syndrome (AIDS)—free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. American Journal of Epidemiology 1989; 130: 530–539
   PubMed Web of Science ®Google Scholar
• Pantaleo G., Graziosi C., Fauci A. S. New concepts in the immunopathogenesis of human immunodeficiency virus infection. New England Journal of Medicine 1989; 328: 327–335
   Google Scholar
• Pedersen C., Lindhardt B. O., Jensen B. L., et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. British Medical Journal 1993; 299: 154–157
   Google Scholar
• Richman D. D., Grimes J. M., Lagakos S. W. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Journal of the Acquired Immunodeficiency Syndrome 1989; 3: 743–746
   Web of Science ®Google Scholar
• Sande M. A., Carpenter C. C., Cobbs C. G., Holmes K. K., Sanford J. P. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA 1990; 270: 2583–2589
   Google Scholar
• Tindall B., Barker S., Donovan B, et al. Characteristics of the acute clinical illness associated with human immunodeficiency virus infection. Archives of Internal Medicine 1993; 148: 945–949
   Google Scholar
• USPHS/IDSA Prevention of Opportunistic Infections Working Group. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: disease-specific recommendations. Clinical Infectious Diseases 1988; 21(1)S32–S43
   Google Scholar
• Volberding P. A., Lagakos S. W., Grimes J. M., et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of the protocol 019 of the AIDS Clinical Trials Group. JAMA 1995; 272: 437–442
   Web of Science ®Google Scholar
• Volberding P. A., Lagakos S. W., Grimes J. M., et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. New England Journal of Medicine 1994; 333: 401–407
   Web of Science ®Google Scholar
• Ward J. W., Depppe D. A., Samson S, et al. Risk of human immunodeficiency virus infection from blood donors who later developed the acquired immunodeficiency syndrome. Annals of Internal Medicine 1995; 106: 61–62
   Google Scholar
• Wei X., Ghosh S. K., Taylor M. E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1987; 373: 117–122
   Google Scholar
• Yarchoan R., Venzon D. J., Pluda J. M., et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Annals of Internal Medicine 1995; 115: 184–189
   Google Scholar